SCHEMBL4248613

SCHEMBL4248613

O=C1OCCc2cc(C3CCCCC3)nc(N3CCCCC3)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ATM Q13315 3/20 0.36
CHRM3 P20309 7/20 0.34
PDE4A P27815 5/20 0.34
PDE4B Q07343 5/20 0.34
PDE4C Q08493 5/20 0.34
PDE4D Q08499 5/20 0.34
CNR2 P34972 3/20 0.34
HRH4 Q9H3N8 2/20 0.34
NPY5R Q15761 2/20 0.34
HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063851 0.82 ALDH1A1 (0.62) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL4483308 0.80 L3MBTL1 (0.34) ALDH1A1LMNAL3MBTL1PDE4APDE4B
SCHEMBL4470420 0.80 HRH4 (0.36) KDM4EALDH1A1HPGDMEN1LMNA
SCHEMBL4467633 0.80 PSD (0.34) LMNAL3MBTL1PDE4APDE4BPDE4C
SCHEMBL4067394 0.78 HSD17B10 (0.47) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL4248277 0.77 HSD17B10 (0.45) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL4746294 0.77 ALDH1A1 (0.43) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL4749859 0.77 ALDH1A1 (0.43) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL4240846 0.76 HPGD (0.55) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL4749923 0.75 KDM4E (0.44) KDM4EALDH1A1HPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 KDM4E 405/4885ALDH1A1 1008/4885HPGD 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.